Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(13 sites)
United States
Madera Family Medical Group ( Site 1004), Madera, California Acevedo Clinical Research Associates ( Site 1029), Miami, Florida University of South Florida-Department of Pediatrics ( Site 1002), Tampa, Florida Cotton O'Neil Research Center ( Site 1039), Topeka, Kansas University of Louisville, Norton Children's Research Institute ( Site 1005), Louisville, Kentucky Saint Louis University Center for Vaccine Development ( Site 1031), St Louis, Missouri Child Health Care Associates ( Site 1035), East Syracuse, New York Tribe Clinical Research, LLC-Pediatrics ( Site 1008), Greenville, South Carolina Tribe Clinical Research - Spartanburg ( Site 1001), Spartanburg, South Carolina Epic Medical Research - Carrollton ( Site 1038), Carrollton, Texas Epic Medical Research- Garland ( Site 1017), Garland, Texas University of Texas Medical Branch ( Site 1020), League City, Texas Pediatric Research of Charlottesville, LLC ( Site 1012), Charlottesville, Virginia